company background image

Eisai TSE:4523 Stock Report

Last Price


Market Cap







08 Aug, 2022


Company Financials +
4523 fundamental analysis
Snowflake Score
Future Growth2/6
Past Performance1/6
Financial Health6/6

4523 Stock Overview

Eisai Co., Ltd. offers pharmaceutical products in Japan.

Eisai Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Eisai
Historical stock prices
Current Share PriceJP¥6,112.00
52 Week HighJP¥9,395.00
52 Week LowJP¥5,011.00
1 Month Change0.26%
3 Month Change10.01%
1 Year Change-33.04%
3 Year Change13.31%
5 Year Change8.10%
Change since IPO275.30%

Recent News & Updates

Shareholder Returns

4523JP PharmaceuticalsJP Market

Return vs Industry: 4523 underperformed the JP Pharmaceuticals industry which returned 6% over the past year.

Return vs Market: 4523 underperformed the JP Market which returned -0.1% over the past year.

Price Volatility

Is 4523's price volatile compared to industry and market?
4523 volatility
4523 Average Weekly Movement3.9%
Pharmaceuticals Industry Average Movement4.1%
Market Average Movement3.9%
10% most volatile stocks in JP Market8.1%
10% least volatile stocks in JP Market2.1%

Stable Share Price: 4523 is not significantly more volatile than the rest of JP stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: 4523's weekly volatility (4%) has been stable over the past year.

About the Company

194111,322Haruo Naito

Eisai Co., Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer’s disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures. The company also provides Lyrica for pain treatment; Dayvigo, an anti-insomnia drug for the treatment of adults with insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; and Halaven, an anticancer agent/microtubule dynamics inhibitor for the treatment of breast cancer and liposarcoma.

Eisai Fundamentals Summary

How do Eisai's earnings and revenue compare to its market cap?
4523 fundamental statistics
Market CapJP¥1.75t
Earnings (TTM)JP¥32.74b
Revenue (TTM)JP¥741.59b


P/E Ratio


P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
4523 income statement (TTM)
Cost of RevenueJP¥173.52b
Gross ProfitJP¥568.08b
Other ExpensesJP¥535.34b

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

Nov 07, 2022

Earnings per share (EPS)114.19
Gross Margin76.60%
Net Profit Margin4.41%
Debt/Equity Ratio11.5%

How did 4523 perform over the long term?

See historical performance and comparison



Current Dividend Yield


Payout Ratio

Does 4523 pay a reliable dividends?

See 4523 dividend history and benchmarks
When do you need to buy 4523 by to receive an upcoming dividend?
Eisai dividend dates
Ex Dividend DateSep 29 2022
Dividend Pay DateNov 21 2022
Days until Ex dividend51 days
Days until Dividend pay date104 days

Does 4523 pay a reliable dividends?

See 4523 dividend history and benchmarks
We’ve recently updated our valuation analysis.


Is 4523 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score


Valuation Score 0/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 4523?

Other financial metrics that can be useful for relative valuation.

4523 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue2.1x
Enterprise Value/EBITDA25.9x
PEG Ratio6.1x

Price to Earnings Ratio vs Peers

How does 4523's PE Ratio compare to its peers?

4523 PE Ratio vs Peers
The above table shows the PE ratio for 4523 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average22.2x
4151 Kyowa Kirin
4528 Ono Pharmaceutical
4507 Shionogi
4578 Otsuka Holdings
4523 Eisai

Price-To-Earnings vs Peers: 4523 is expensive based on its Price-To-Earnings Ratio (53.5x) compared to the peer average (22.2x).

Price to Earnings Ratio vs Industry

How does 4523's PE Ratio compare vs other companies in the JP Pharmaceuticals Industry?

Price-To-Earnings vs Industry: 4523 is expensive based on its Price-To-Earnings Ratio (53.5x) compared to the JP Pharmaceuticals industry average (18.1x)

Price to Earnings Ratio vs Fair Ratio

What is 4523's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

4523 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio53.5x
Fair PE Ratio24.3x

Price-To-Earnings vs Fair Ratio: 4523 is expensive based on its Price-To-Earnings Ratio (53.5x) compared to the estimated Fair Price-To-Earnings Ratio (24.3x).

Share Price vs Fair Value

What is the Fair Price of 4523 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 4523 (¥6112) is trading above our estimate of fair value (¥5272.74)

Significantly Below Fair Value: 4523 is trading above our estimate of fair value.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is lower than the current share price.

Discover undervalued companies

Future Growth

How is Eisai forecast to perform in the next 1 to 3 years based on estimates from 11 analysts?

Future Growth Score


Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 4523's forecast earnings growth (8.8% per year) is above the savings rate (0.04%).

Earnings vs Market: 4523's earnings (8.8% per year) are forecast to grow faster than the JP market (8.7% per year).

High Growth Earnings: 4523's earnings are forecast to grow, but not significantly.

Revenue vs Market: 4523's revenue (3.2% per year) is forecast to grow slower than the JP market (4.4% per year).

High Growth Revenue: 4523's revenue (3.2% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 4523's Return on Equity is forecast to be low in 3 years time (8.3%).

Discover growth companies

Past Performance

How has Eisai performed over the past 5 years?

Past Performance Score


Past Performance Score 1/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: 4523 has a large one-off loss of ¥14.2B impacting its June 30 2022 financial results.

Growing Profit Margin: 4523's current net profit margins (4.4%) are lower than last year (8.8%).

Past Earnings Growth Analysis

Earnings Trend: 4523's earnings have grown by 6.9% per year over the past 5 years.

Accelerating Growth: 4523's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 4523 had negative earnings growth (-45.3%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (17.2%).

Return on Equity

High ROE: 4523's Return on Equity (3.8%) is considered low.

Discover strong past performing companies

Financial Health

How is Eisai's financial position?

Financial Health Score


Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: 4523's short term assets (¥620.9B) exceed its short term liabilities (¥301.9B).

Long Term Liabilities: 4523's short term assets (¥620.9B) exceed its long term liabilities (¥142.6B).

Debt to Equity History and Analysis

Debt Level: 4523 has more cash than its total debt.

Reducing Debt: 4523's debt to equity ratio has reduced from 37.8% to 11.5% over the past 5 years.

Debt Coverage: 4523's debt is well covered by operating cash flow (143.3%).

Interest Coverage: 4523 earns more interest than it pays, so coverage of interest payments is not a concern.

Balance Sheet

Discover healthy companies


What is Eisai current dividend yield, its reliability and sustainability?

Dividend Score


Dividend Score 4/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage


Current Dividend Yield

Upcoming Dividend Payment

TodayAug 09 2022Ex Dividend DateSep 29 2022Dividend Pay DateNov 21 202253 days from Ex DividendBuy in the next 51 days to receive the upcoming dividend

Dividend Yield vs Market

Notable Dividend: 4523's dividend (2.62%) is higher than the bottom 25% of dividend payers in the JP market (1.63%).

High Dividend: 4523's dividend (2.62%) is low compared to the top 25% of dividend payers in the JP market (3.62%).

Stability and Growth of Payments

Stable Dividend: 4523's dividends per share have been stable in the past 10 years.

Growing Dividend: 4523's dividend payments have increased over the past 10 years.

Earnings Payout to Shareholders

Earnings Coverage: With its high payout ratio (140.1%), 4523's dividend payments are not well covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: With its reasonably low cash payout ratio (48.6%), 4523's dividend payments are well covered by cash flows.

Discover strong dividend paying companies


How experienced are the management team and are they aligned to shareholders interests?


Average management tenure


Haruo Naito (75 yo)





Mr. Haruo Naito has been the Chief Executive Officer of Eisai Co., Ltd. since June 2003 and has been its Representative Corporate Officer since June 2004. Mr. Naito has been President and Representative Di...

CEO Compensation Analysis

Compensation vs Market: Haruo's total compensation ($USD923.24K) is below average for companies of similar size in the JP market ($USD1.51M).

Compensation vs Earnings: Haruo's compensation has been consistent with company performance over the past year.

Leadership Team

Experienced Management: 4523's management team is not considered experienced ( 0.6 years average tenure), which suggests a new team.

Board Members

Experienced Board: 4523's board of directors are not considered experienced ( 2.2 years average tenure), which suggests a new board.


Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Company Information

Eisai Co., Ltd.'s employee growth, exchange listings and data sources

Key Information

  • Name: Eisai Co., Ltd.
  • Ticker: 4523
  • Exchange: TSE
  • Founded: 1941
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: JP¥1.752t
  • Shares outstanding: 286.72m
  • Website:

Number of Employees


  • Eisai Co., Ltd.
  • 4-6-10, Koishikawa
  • Bunkyo-ku
  • Tokyo
  • 112-8088
  • Japan


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/08/08 00:00
End of Day Share Price2022/08/08 00:00
Annual Earnings2022/03/31

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.